Vertex creates new possibilities in medicine to cure diseases and improve people's lives. We work with leading researchers, doctors, public health experts and other collaborators who share our vision for transforming the lives of people with serious diseases, their families and society.

from http://www.vrtx.com/

Research Grants 78 show all


$4.5M
2015

$372.2K
2016

$131.4K
2017

$2.6M
2018

$16.5M
2019

Publications 5 show all

  • 1
    Antifungal Agents/pharmacokinetics
  • 1
    Drug Compounding/methods
  • 1
    Drug Liberation
  • 1
    Excipients/chemistry
  • 1
    Flucytosine/pharmacokinetics
  • 1
    Gene Expression Profiling
  • 1
    Glioblastoma/drug therapy
  • 1
    Glioblastoma/genetics
  • 1
    Hepatocyte Growth Factor/metabolism
  • 1
    Itraconazole/pharmacokinetics

Patents 8,880show all

  • 3,617
    C07D - Heterocyclic compounds
  • 1,655
    A61K - Preparations for medical, dental, or toilet purposes
  • 656
    C07K - Peptides
  • 421
    C07C - Acyclic or carbocyclic compounds
  • 362
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 353
    C12N - Microorganisms or enzymes
  • 259
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 220
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 209
    Y02A - Technologies for adaptation to climate change
  • 107
    C07B - General methods of organic chemistry

Clinical Trials 483show all

216Phase 3100Phase 296N/A35Phase 121Other

SEC Filings show all


229
8-K

73
10-Q

22
10-K

1
D

Contact Information

Cambridge, MA
United States

SEC Form D Funding Events

DateOfferedSoldType
2009-03-18$2,397,225$2,397,225Equity

Key Executives

  • Joshua S. Boger
    Executive Officer, Director
  • Matthew W. Emmens
    Executive Officer, Director
  • Ian F. Smith
    Executive Officer
  • Kenneth S. Boger
    Executive Officer
  • Roger W. Brimblecombe
    Director
  • Eric K. Brandt
    Director
  • Stuart J.m. Collinson
    Director
  • Eugene H. Cordes
    Director
  • Bruce I. Sachs
    Director
  • Charles A. Sanders
    Director
  • Elaine S. Ullian
    Director
  • Freda C. Lewis-Hall
    Executive Officer
  • Kurt C. Graves
    Executive Officer
  • Richard C. Garrison
    Executive Officer
  • Lisa Kelly-Croswell
    Executive Officer
  • Amit K. Sachdev
    Executive Officer
  • Paul M. Silva
    Executive Officer
  • Peter Mueller
    Executive Officer